Article Text

PDF
OP0189 Tumor necrosis factor inhibitor treatment reduces spinal radiographic progression in ankylosing spondylitis by decreasing disease activity: a longitudinal analysis in a large prospective cohort
  1. C Molnar1,
  2. A Scherer1,
  3. X Baraliakos2,
  4. M de Hooge3,
  5. R Micheroli4,
  6. P Exer5,
  7. R Kissling6,
  8. G Tamborrini5,
  9. L Wildi4,
  10. M Nissen7,
  11. P Zufferey8,
  12. J Bernhard9,
  13. U Weber10,
  14. R Landewé11,
  15. D van der Heijde3,
  16. A Ciurea4
  1. 1SCQM, Zurich, Switzerland
  2. 2Rheumazentrum, Herne, Germany
  3. 3LUMC, Leiden, Netherlands
  4. 4USZ, Zurich
  5. 5Private Practice, Basel
  6. 6Balgrist, Zurich
  7. 7HCUGE, Geneva
  8. 8CHUV, Lausanne
  9. 9Bürgerspital, Solothurn, Switzerland
  10. 10Univ Southern Denmark, Odense, Denmark
  11. 11AMC, Amsterdam, Netherlands

Abstract

Background Whether tumor necrosis factor inhibitors (TNFi) have an influence on radiographic progression in ankylosing spondylitis (AS) remains controversial.

Objectives To investigate the impact of TNFi use on spinal radiographic progression in AS.

Methods Patients fulfilling the modified NY Criteria for AS (as assessed by central reading) in the Swiss Clinical Quality Management Cohort with at least 2 years of clinical and radiographic follow-up were included. Spinal X-rays were taken every 2 years and scored independently by 2 blinded readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in chronological time order. Average score of the readers was used. Radiographic progression was defined as an increase by ≥2 mSASSS units over 2 years. The relationship between TNFi use before a 2 year X-ray interval and progression within the interval was investigated using binomial generalized estimating equation models with adjustment for potential confounding and multiple imputation of missing covariate data. Ankylosing Spondylitis Disease Activity Score (ASDAS) was regarded as a potential intermediate variable mediating the effect of TNFi on radiographic progression. It was added to the model as a time-varying variable in a sensitivity analysis.

Results A total of 420 patients with AS contributed to data for 597 x-ray intervals in adjusted analyses (1–5 intervals per patient); BL characteristics: male sex 66%, HLA-B27 81%, mean (SD) age 40.4 (10.9) years, disease duration 13.9 (9.8) years, mSASSS 6.4 (12.4), ASDAS 2.8 (1.1)). 39% of the patients were already on TNFi at first X-ray. Mean mSASSS progression in 2 years was 0.9 (2.7) units. The multivariable model (Table) shows that prior use of TNFi reduced the odds of progression in the next 2 year interval by 49% (odds ratio (OR) 0.51, 95% confidence interval (CI) 0.28–0.92, p=0.03). BL mSASSS and male sex also significantly affected progression. Adding ASDAS as a covariate to the model decreased the estimated effect of TNFi on progression: OR 0.65, 95% CI 0.36–1.17, p=0.15. In this model, a decrease in ASDAS by 1 unit would lower the odds for progression by 0.62 (p=0.001).

Table 1.

Longitudinal multivariable analysis of radiographic progression

Conclusions TNFi seem to reduce radiographic progression in patients with AS and this effect is mediated, at least in part, by a decrease in disease activity.

Acknowledgements Supported by the Stiftung für Rheumaforschung and a research grant from the investigator initiated studies program of MSD.

Disclosure of Interest C. Molnar: None declared, A. Scherer: None declared, X. Baraliakos: None declared, M. de Hooge: None declared, R. Micheroli: None declared, P. Exer: None declared, R. Kissling: None declared, G. Tamborrini: None declared, L. Wildi: None declared, M. Nissen: None declared, P. Zufferey: None declared, J. Bernhard Consultant for: Merck Sharp & Dohme, Pfizer, Roche, U. Weber Consultant for: Abbvie, R. Landewé: None declared, D. van der Heijde: None declared, A. Ciurea Consultant for: Abbvie, Celgene, Eli Lilly, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, UCB

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.